CORAL GABLES, FL / ACCESSWIRE / March 4, 2019 / Following the recent passing of positive legislation, the marijuana stock market has become a hotbed of conversation. In fact, every single U.S. state lining the west coast (Alaska, Washington, Oregon, California) has legalized the use of recreational, as well as medicinal, cannabis. To put it simply, lawmakers finally recognized that marijuana had no business sharing Schedule 1 status with drugs like Heroine and LSD. After years of public condemnation, people have finally come to their senses and recognized the multitude of benefits presented by cannabis products. Considering the nascency of the cannabis sector, investors looking for fresh opportunities could benefit from looking into cannabis. Global Consortium Inc (OTC:GCGX), India Globalization Capital Inc (NYSE American: IGC), Aphria Inc (NYSE: APHA, TSX: APHA), and Intellipharmaceutics International Inc (NASDAQ:IPCI) are 4 pot stocks worth looking into this week.
Global Consortium Inc (OTC:GCGX) is a company that you might not have heard of but could benefit from checking out as we continue in this new year. Global Consortium is putting in the work to become one of the industry leaders in terms of hemp-derived CBD products, and the market has responded favorably to these strategic moves.
Global Consortium Inc (OTC:GCGX) has made it a point to build a corporate framework to support its endeavors, recent of which have included building a "Cannabis Mall." According to reports, the project, once completed, will house manufacturing, distribution, delivery, retail, testing, and cultivation all under one 64,000 sq. ft building.
In recent news, Global Consortium Inc (OTC:GCGX) today announced the Company will allow six of its shareholders to tour their "Cannabis Mall." Global Consortium is inviting all shareholders to register for this opportunity to tour the facility and enjoy a Q&A session and lunch with Tom Roland our Chief Operating Officer. Taking the form of a contest, the winners will be flown out to California for two nights. On the second day, you will be transported to the facility where you will meet up with Tom Roland, who will give you a guided tour of the operations facility.
India Globalization Capital Inc (IGC) announced earlier this month that the Company had successfully challenged NYSE American's decision to delist the common stock of the Company from trading on the Exchange under the Exchange's appeal procedures. In a written decision issued on February 20, 2019, a review panel of the Exchange unanimously ruled to set aside the Exchange's October 29, 2018 decision to delist the Company's common stock, finding that the Company has not discontinued the business it conducted at the time it was first listed on the Exchange.
Following the announcement, Ram Makunda, CEO of IGC, commented, "we are very pleased that the Exchange procedures allowed us the opportunity to challenge the decision to delist and to present our case to a review panel. We are happy with the result, and we believe the decision accurately shows our efforts to continue and expand our operations within our two existing business lines."
Aphria Inc (APHA) found itself in headlines today when the Company announced that Health Canada has granted the Company its license amendment, permitting Aphria to commence production in an additional 800,000 square feet of facilities at its Aphria One location, as part of the Company's completed Part IV and Part V expansions.
Irwin Simon, Interim CEO of Aphria, stated, "this is a major milestone for Aphria on its path to becoming a leading global cannabis producer, as well as a positive development greatly anticipated by the Canadian cannabis industry. Aphria's progress expanding production and automation is essential to our strategy of securing scale and long-term advantages that enable the evolution of the cannabis industry through product and brand innovation."
Intellipharmaceutics International Inc (IPCI) saw impressive gains in the market on Monday, with shares up 13.57%, trading at $0.31 just before noon. The pharmaceutical company earlier this month reported results of operations for the year ended November 30, 2018, which showed revenues of $1.7 million for the year ended November 30, 2018, versus $5.5 million for the year ended November 30, 2017.
Dr. Isa Odidi, CEO of Intellipharmaceutics, said, "we believe our fiscal 2018 results are a positive reflection of our focus on our Oxycodone ER, Oxycodone IR, and other 505(b)(2) development programs, despite financially challenging circumstances. We continue to move forward with our existing development programs, manufacturing, and commercial efforts while also considering new product candidates and markets.''
MarijuanaStocks.com is the leading web destination for all things cannabis. Investors can find marijuana-related financial, medical, legal, and social news anytime day or night. Writers are invited to submit cannabis related articles for publication.
Except for the historical information presented herein, matters discussed in this article contain forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. MAPH Enterprises LLC which owns www.MarijuanaStocks.com is not registered with any financial or securities regulatory authority and does not provide nor claims to provide investment advice or recommendations to readers of this release.
MAPH Enterprises LLC, which owns www.MarijuanaStocks.com, may from time to time have a position in the securities mentioned herein and may increase or decrease such positions without notice. For making specific investment decisions, readers should seek their own advice. MAPH Enterprises LLC, which owns www.MarijuanaStocks.com, may be compensated for its services in the form of cash-based compensation or equity securities in the companies it writes about, or a combination of the two.
Pursuant to an agreement between an affiliate of MAPH Enterprises, LLC (owners of MarijuanaStocks.com), Midam Ventures LLC and Global Consortium Inc. (GCGX), Midam has been paid $20,000 from Global Consortium Inc. (GCGX) for a period from January 22, 2019, to February 22, 2019. Midam has been paid $20,000 by a 3rd Party, VS Services LLC for coverage on Global Consortium Inc. (GCGX) for a period from February 26, 2019, to March 26, 2019. We may buy or sell additional shares of (GCGX) in the open market at any time, including before, during or after the Website and Information, to provide public dissemination of favorable Information about Global Consortium Inc. (GCGX). For previous compensation and disclaimer information, click here.
View source version on accesswire.com: